Company Of The Day: Pfizer
What?
The U.S. Centers for Disease Control and Prevention has formally authorized the Pfizer (NYSE:PFE) – BioNTech Covid-19 vaccine for children between the ages of 5 and 11 years old.
So What?
Relevant Articles
- After A 30% Fall In A Year Is Pfizer Stock A Better Pick Over Merck?
- Should You Pick Pfizer Stock At $30 After A 30% Fall In A Year?
- Should You Pick Pfizer Stock At $30?
- Down 25% In A Year Will Pfizer Stock Rebound To Its Pre-Inflation Shock Level?
- Will Pfizer Stock See Higher Levels Post Q1 Earnings?
- Is Pfizer Stock Undervalued At $40?
Pfizer stock remains up by about 24% year-to-date, driven largely by strong demand for the Covid-19 vaccine. Now, the approval for younger children should expand the addressable market for the vaccine further.
See Our Complete Analysis For Pfizer
What if you’re looking for a more balanced portfolio instead? Here’s a high-quality portfolio that’s beaten the market consistently since 2016.
Invest with Trefis Market Beating Portfolios
See all Trefis Price Estimates